05
054670.KQ Daehan New Pharm Co. Ltd
- Market cap
- KRW 71.6B
- P/E
- 3.0x
- P/B
- 0.48x
- ROE
- 19.2%
- Dividend yield
- 1.96%
- Fundamental score
- 3.2/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 054670.KQ undervalued?
Graham numberThe Graham number of Daehan New Pharm Co. Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daehan New Pharm Co. Ltd fundamental analysis
16 of 22 checks passedROE 1/2
Moderate return on equity (19.2%), between 10% and 20%.
ROA 1/1
Return on assets (10.1%) is above the industry median (1.4%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-1.4%) is below the industry median (1.8%).
Revenue Growth 1/2
Revenue grew 0.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (39.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 20.3x against interest expense, well covered.
PE vs Market 1/1
PE (3.0x) is below the market median (11.3x).
PE vs Industry 1/1
PE (3.0x) is below the industry median (11.4x).
PBV 1/1
Price to book (0.5x) is below the industry median (0.9x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 1.4, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.0%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 9.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Daehan New Pharm Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anestheti…
Full company profileDaehan New Pharm Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daehan New Pharm Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 109B | 131B | 120B | 134B | 150B | 167B | 198B | 204B | 202B | 202B | 222B |
| Gross Profit | 60.9B | 70.0B | 63.2B | 72.4B | 76.6B | 84.0B | 90.5B | 94.0B | 96.9B | 92.3B | 92.4B |
| Operating Income | 245M | 11.4B | 19.9B | 20.7B | -9.27B | 25.1B | 36.5B | 18.8B | 18.7B | 11.7B | 10.6B |
| EBITDA | - | - | - | - | - | - | 39.0B | 25.9B | 24.2B | 21.0B | 43.2B |
| Net Income | -5.67B | -20.6B | 2.45B | 15.2B | -9.93B | 15.7B | 24.3B | 12.5B | 15.5B | 15.3B | 28.5B |
| EPS | -404 | -1,466 | 175 | 1,086 | -707 | 1,118 | 1,733 | 894 | 1,102 | 1,087 | 2,032 |
| Balance Sheet | |||||||||||
| Total Assets | 131B | 122B | 109B | 128B | 133B | 158B | 169B | 177B | 221B | 271B | 281B |
| Total Liabilities | 59.5B | 70.1B | 65.7B | 66.8B | 75.9B | 75.2B | 66.4B | 67.6B | 95.8B | 131B | 132B |
| Shareholders' Equity | 71.2B | 51.7B | 43.1B | 61.1B | 57.1B | 82.5B | 103B | 109B | 125B | 140B | 149B |
| Cash & Short-term Investments | 10.2B | 5.94B | 8.17B | 17.2B | 20.4B | 21.5B | 28.6B | 23.0B | 36.7B | 20.0B | 15.3B |
| Total Debt | 33.0B | 36.8B | 31.3B | 25.8B | 36.0B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.75B | -2.42B | 20.5B | 22.9B | 13.5B | 16.6B | 14.3B | 12.6B | 18.9B | 5.06B | -6.28B |
| Capital Expenditure | 4.57B | 1.25B | 1.73B | 9.08B | 9.46B | 10.6B | 3.51B | 9.93B | 34.3B | 51.1B | 13.3B |
| Free Cash Flow | - | - | - | 10.2B | 3.74B | 5.90B | 10.7B | 2.50B | -15.3B | -46.0B | -19.6B |
| Ratios | |||||||||||
| ROE | -8.0% | -39.8% | 5.7% | 25.0% | -17.4% | 19.0% | 23.6% | 11.5% | 12.3% | 10.9% | 19.2% |
| ROA | -4.3% | -16.9% | 2.3% | 11.9% | -7.5% | 10.0% | 14.4% | 7.1% | 7.0% | 5.6% | 10.1% |
| Net Profit Margin | -5.2% | -15.7% | 2.1% | 11.4% | -6.6% | 9.4% | 12.3% | 6.1% | 7.7% | 7.5% | 12.9% |
| Debt to Equity | 0.46x | 0.71x | 0.73x | 0.42x | 0.63x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Daehan New Pharm Co. Ltd dividends
- Dividend yield
- 1.96%
- Forward dividend
- 100.00 KRW
- Payout ratio
- 9.2%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 1.40B | 100 | 9.2% |
| 2024 | KRW 1.40B | 100 | 9.1% |
| 2023 | KRW 1.40B | 100 | 11.2% |
| 2022 | KRW 1.12B | 80 | 4.6% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | KRW 702M | 50 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 602:579 on Nov 28, 2005.
Who owns Daehan New Pharm Co. Ltd
- Insiders 40.85%
- Institutions 0.26%
- Public & others 58.90%
- Shares outstanding 14.0M
- Free float 8.15M
Daehan New Pharm Co. Ltd company profile
- Company name
- Daehan New Pharm Co. Ltd
- Ticker
- 054670.KQ
- ISIN
- KR7054670005
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Fiscal year end
- December
- Address
- 66 Pharmaceutical Complex 1-gil, Hwaseong-si, South Korea, 18622
- Phone
- 82 3 1778 2600
- Website
- dhnp.co.kr
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products. The company also provides animal health and nutrition products; health supplements; and aesthetic/medical devices. The company was formerly known as Daehan New Pharm Co., Ltd and changed its name to Daehan Nupharm Co.,Ltd. in March 2025. Daehan Nupharm Co.,Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.
Daehan New Pharm Co. Ltd management
9- Mr. Wonseok LeeCEO & Executive Director
- Mr. Jeong-Su ChoiExecutive Director & Head of Finance Department · born 1967
- Mr. Sang-Ho ParkExecutive Director & Head of Business Management Division · born 1967
- Mr. Dong-Hoon YangExecutive Director & Head of New Business Division · born 1968
- Mr. YeongDong KimExecutive Director & Head of Overseas Business Division · born 1969
- Mr. SeongGil MaExecutive Director & Head of Management Innovation Division · born 1971
- Mr. GwangHo ChoDirector & Head of Pharmaceutical Business Division · born 1978
- Mr. JongSeong KimExecutive Director & Head of Pharmaceutical Business Division · born 1968
- Mr. SeongUn ChoExecutive Director & Head of Academic Development Division · born 1964